Necdin modulates leukemia-initiating cell quiescence and chemotherapy response

Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Chonghua, Kobayashi, Michihiro, Chen, Sisi, Nabinger, Sarah C., Gao, Rui, Liu, Stephen Z., Asai, Takashi, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675657/
https://www.ncbi.nlm.nih.gov/pubmed/29152105
http://dx.doi.org/10.18632/oncotarget.20999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675657/
https://www.ncbi.nlm.nih.gov/pubmed/29152105
http://dx.doi.org/10.18632/oncotarget.20999

Ejemplares similares